Last Updated: November 8, 2026

Details for Patent: 11,969,409

Name: Drug Patent Intelligence for US Patent 11969409
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 11,969,409 protect, and when does it expire?

Patent 11,969,409 protects OTEZLA XR and is included in one NDA.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: 11,969,409

Title:	Formulations of apremilast
Abstract:	Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).
Inventor(s):	Nathan Bennette, William Brett Caldwell, Christi Hostetler, Kazden Ingram, Dory King, Kyle Kyburz, Alison Viles
Assignee:	Amgen Inc
Application Number:	US18/196,718
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 11,969,409

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,969,409

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	125988	⤷ Start Trial
Australia	2022280939	⤷ Start Trial
Brazil	112023024564	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.